Centanafadine
Sponsors
Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions
ADHDAnxietyAttention Deficit Hyperactivity DisorderAttention-deficit Hyperactivity DisorderBinge-Eating DisorderGeneralized AnxietyHealthy Adult ParticipantsMajor Depressive Disorder
Phase 1
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
CompletedNCT04398225
Start: 2020-06-11End: 2021-04-01Updated: 2022-06-02
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
CompletedNCT04786730
Start: 2021-03-09End: 2023-04-26Updated: 2023-07-13
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
CompletedNCT07314333
Start: 2026-02-05End: 2026-04-15Updated: 2026-05-05
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
CompletedNCT07486895
Start: 2023-03-08End: 2023-05-18Updated: 2026-03-23
Phase 2
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
CompletedNCT04081363
Start: 2019-10-07End: 2019-12-21Updated: 2023-01-13
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
CompletedNCT05066724
Start: 2021-09-15End: 2022-05-31Updated: 2025-06-13
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
CompletedNCT05113953
Start: 2021-12-22End: 2022-08-19Updated: 2025-09-09
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
CompletedNCT05536414
Start: 2022-09-12End: 2025-05-16Updated: 2026-05-14